Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19

Research output: Contribution to journal › Letter

Original language	English
Number of pages	3
Journal	European Journal of Clinical Pharmacology
Early online date	4 Oct 2020
DOIs	https://doi.org/10.1007/s00228-020-03008-6
Publication status	E-pub ahead of print - 4 Oct 2020

Cite this

@article{a717875ff62b42f19075b5ca9321756f,

title = "Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19",

keywords = "COVID-19, Clinical trials, remdesivir",

author = "Kow, {Chia Siang} and Mamoon Aldeyab and Hasan, {Syed Shahzad}",

year = "2020",

month = oct,

day = "4",

doi = "10.1007/s00228-020-03008-6",

language = "English",

journal = "European Journal of Clinical Pharmacology",

issn = "0031-6970",

publisher = "Springer Verlag",

}

TY - JOUR

T1 - Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19

AU - Kow, Chia Siang

AU - Aldeyab, Mamoon

AU - Hasan, Syed Shahzad

PY - 2020/10/4

Y1 - 2020/10/4

KW - COVID-19

KW - Clinical trials

KW - remdesivir

U2 - 10.1007/s00228-020-03008-6

DO - 10.1007/s00228-020-03008-6

M3 - Letter

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

ER -